Oleoylethanolamide-producing Lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese male mice
Brain, Behavior, and Immunity · 2025
DOI: 10.1016/j.bbi.2025.02.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025. Verfasst von Luisa Seguella und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy. Electronic address: lu…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Endocannabinoids, Oleic Acids, Lacticaseibacillus paracasei. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, Ministero dell'Istruzione dell'Università e della Ricerca.
Abstract (Originalsprache)
Metabolic and mood disorders elicited by chronic exposure of high-fat diet (HFD) are often associated with intestinal dysbiosis and persistent low-grade inflammation in the small intestine. This leads to remodeling of the epithelial barrier with disruption of the neuroepithelial circuits that control energy homeostasis by the gut-brain axis. Therefore, therapies that restoreintestinal microbial niche and barrier function are promising candidates to counter peripheral metabolic challenges that affect behaviors controlled by the brain. The endogenous oleoylethanolamine (OEA) was found to shape the intestinal microbiota profile towards a "lean-like phenotype", ameliorating pathological profiles of metabolic diseases. Further, OEA displays beneficial effects in several cognitive paradigms and preserves the epithelial barrier integrity, acting as an intestinal "gate-keeper". Here, we developed an "intestinal OEA factory" for the in-situ and controlled release of OEA by using a probiotic-based delivery system. We engineered the Lactobacillus paracasei F19 (LP) to express the human N-acylphosphatidylethanolamine-preferring phospholipase D (NAPEpld) gene and to produce OEA in response to dietary ultra-low oleate supply. We treated 12-week HFD male mice with oleate-probiotic formulations and assessed their impact on metabolic and behavioral dysfunctions, and microbiota-gut-brain signaling after 8 weeks of treatment. NAPE-expressing LP (pNAPE-LP) led to significant reduced weight loss and improved metabolic dysfunction in HFD-treated mice. Further, a parallel improvement in depressive- and anxiety-like phenotypes was associated with the duodenal barrier function retrieval, the restoration of the Firmicutes/Bacteroidetes ratio, and an increase in beneficial bacteria, such as Lactobacillus, Prevotella, and Parabacteroides. The HFD-driven changes both in the enteric and central nervous system were prevented by pNAPE-LP/oleate treatment. Collectively, our data suggest that these effects were mediated by the oleate-dependent release of OEA by pNAPE-LP since no significant effects were observed in HFD mice treated with the native probiotic alone (pLP). This oleate-regulated delivery system of OEA is a safe and efficient probiotic-based strategy for the treatment of metabolic syndrome and related behavioral disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy. Electronic address: luisa.seguella@uniroma1.it.
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy. Electronic address: chiara.corpetti@uniroma1.it.
- Department of Anatomy and Cell Biology, China Medical University, N0.77 Puhe Road, Shenbei New District, Shenyang City, Liaoning Province, PR China. Electronic address: lvjie@cmu.edu.cn.
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Via Pansini 5, 80131 Naples, Italy. Electronic address: marcella.pesce@unina.it.
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy. Electronic address: silvia.basilifranzin@uniroma1.it.
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy. Electronic address: irene.palenca@uniroma1.it.
Förderung
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Ministero dell'Istruzione dell'Università e della Ricerca
Zitieren
APA
Seguella, L., Corpetti, C., Lu, J., Pesce, M., Franzin, S. B., Palenca, I., Zilli, A., Vincenzi, M., Caprioli, D., Paytuví-Gallart, A., Sanseverino, W., Rurgo, S., Sarnelli, G., & Esposito, G. (2025). Oleoylethanolamide-producing Lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese male mice. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2025.02.014
Vancouver
Seguella L, Corpetti C, Lu J, Pesce M, Franzin SB, Palenca I, et al. Oleoylethanolamide-producing Lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese male mice. Brain, Behavior, and Immunity. 2025. doi:10.1016/j.bbi.2025.02.014
BibTeX
@article{Seguella2025,
author = {Seguella, Luisa and Corpetti, Chiara and Lu, Jie and Pesce, Marcella and Franzin, Silvia Basili and Palenca, Irene and Zilli, Aurora and Vincenzi, Martina and Caprioli, Daniele and Paytuví-Gallart, Andreu and Sanseverino, Walter and Rurgo, Sara and Sarnelli, Giovanni and Esposito, Giuseppe},
title = {Oleoylethanolamide-producing Lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese male mice},
journal = {Brain, Behavior, and Immunity},
year = {2025},
doi = {10.1016/j.bbi.2025.02.014}
}
EUVIMED